Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Jan 14, 2026
- Closes
- Feb 11, 2027 (in 118 days)
Similar opportunities open now
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Sep 2027
- Limited Competition: Small Grant Program for Mentored Research Career Development Award Recipients (R03) (Clinical Trials Not Allowed)Same funderOpenNational Institutes of HealthCloses Jul 2029
Classification and identifiers
- Solicitation number
- RFA-CA-28-004
- Assistance listing (CFDA)
- 93.394
Amount
Amount not listed here. Check the official program.
Who can apply
Other Eligible ApplicantsFor the NCTN Biobanks: Eligibility is limited to an institution/entity that is a recipient of an existing NCTN biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-002. For the EET Biobank: Eligibility is limited to the institution/entity that is a recipient of an existing EET biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-003.
About this opportunity
Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of the two distinct biospecimen banking resources: The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), and The Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) support the Experimental Therapeutics Clinical Trials Network (ETCTN) and NCI-supported other early phase and experimental clinical trials. The objective is to maintain these robust national resources for continuing the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resourc...